Posted: 23 January
Adherium Limited, a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce that it has commenced production and market release of the new, next generation Hailie sensors with physiological parameters connecting GlaxoSmithKline (GSK) ELLIPTA inhalers for monitoring Asthma and Chronic Obstructive Pulmonary Disease (COPD).
Mr Rick Legleiter, Adherium Chief Executive Officer, commented, “Purchase orders are in house and more remain in the pipeline. This latest commercial release will bring us new partnerships as our medication coverage increases by expanding our portfolio in the market by adding to our value proposition with physiological parameter capabilities. I am excited to see where this takes the Company into the new year.”
This product rollout adds to Adherium’s growing Hailie sensor portfolio in the market with US FDA 510(k) clearances. Adherium offers the only 510(k) cleared sensor on the market with respiratory flow rate data and adherence tracking feedback at the time of medication use.
Preventable hospitalisations cost the US health system alone US$34 billion annually. Financial support of the market adoption of digital health innovations is encouraged by the United States Centers for Medicare & Medicaid Services (CMS) reimbursement for remote patient monitoring. The Hailie platform’s additional physiological parameters enhance monitoring services to patients with severe, uncontrolled, and difficult to treat respiratory diseases by providing better management tools for them and their doctors.
Mr Francis White, Vice President of Global Business Development, commented “this is a major step in our FY23 objective of further establishing remote patient monitoring revenue. This will set up the Company for its FY24 market validation objective”.
